Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin.
D000150:Acinetobacter / Q000302:isolation & purification; D001419:Bacteria; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D001439:Bacteroides / Q000302:isolation & purification; D002228:Carbenicillin / Q000008:administration & dosage / Q000627:therapeutic use*; D002512:Cephalothin / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D007709:Klebsiella / Q000302:isolation & purification; D008297:Male; D009369:Neoplasms / Q000150:complications*; D011511:Proteus / Q000302:isolation & purification; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D013997:Time Factors
D005839:Gentamicins; D002228:Carbenicillin; D002512:Cephalothin